Shreehas Tambe, CEO & Managing Director, Biocon Biologics said, "The approval of Vevzuo and Evfraxy in Europe underscores our ...

Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, for treating bone diseases and related conditions ...

Denosumab biosimilars Vevzuo and Evfraxy are used for treating various bone diseases. The approvals mark a key step in the ...

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...

Biocon Biologics receives European Commission approval for Vevzuo and Evfraxy, biosimilars of Denosumab, used to treat ...

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, ...